AstraZeneca PLC Files 6-K Report

TL;DR

AZN filed a routine 6-K, confirming 20-F reporting for October 2025.

AI Summary

AstraZeneca PLC filed a Form 6-K on October 1, 2025, reporting as a foreign issuer. The filing indicates that AstraZeneca is submitting its reports under Form 20-F, which is typical for companies incorporated outside the US. The report covers the month of October 2025 and provides standard company information.

Why It Matters

This filing is a routine disclosure for foreign issuers like AstraZeneca, providing standard updates to the SEC and investors about their reporting status.

Risk Assessment

Risk Level: low — This is a standard, routine filing for a foreign issuer and does not contain new material financial or operational information.

Key Players & Entities

• AstraZeneca PLC (company) — Filer of the 6-K report
• 001-11960 (company) — SEC File Number for AstraZeneca PLC
• 1 Francis Crick Avenue (company) — Business and mailing address of AstraZeneca PLC
• Cambridge Biomedical Campus (company) — Business and mailing address of AstraZeneca PLC
• CB2 0AA (company) — ZIP code for AstraZeneca PLC's address
• 011 44 20 7304 5000 (company) — Business phone number for AstraZeneca PLC
• ZENECA GROUP PLC (company) — Former company name of AstraZeneca PLC
• 19930422 (company) — Date of name change from ZENECA GROUP PLC

FAQ

From the Filing

0001654954-25-011310.txt : 20251001 0001654954-25-011310.hdr.sgml : 20251001 20251001101919 ACCESSION NUMBER: 0001654954-25-011310 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20251001 FILED AS OF DATE: 20251001 DATE AS OF CHANGE: 20251001 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ASTRAZENECA PLC CENTRAL INDEX KEY: 0000901832 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11960 FILM NUMBER: 251362895 BUSINESS ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: 1 FRANCIS CRICK AVENUE STREET 2: CAMBRIDGE BIOMEDICAL CAMPUS CITY: CAMBRIDGE PROVINCE COUNTRY: X0 ZIP: CB2 0AA BUSINESS PHONE: 011 44 20 7304 5000 MAIL ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: 1 FRANCIS CRICK AVENUE STREET 2: CAMBRIDGE BIOMEDICAL CAMPUS CITY: CAMBRIDGE PROVINCE COUNTRY: X0 ZIP: CB2 0AA FORMER COMPANY: FORMER CONFORMED NAME: ZENECA GROUP PLC DATE OF NAME CHANGE: 19930422 6-K 1 a5115b.htm TOTAL VOTING RIGHTS a5115b   FORM 6-K   SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     Report of Foreign Issuer   Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934   For the month of October 2025    Commission File Number: 001-11960   AstraZeneca PLC   1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA United Kingdom     Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F X Form 40-F __   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______   Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.   Yes __ No X   If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________           AstraZeneca PLC   INDEX TO EXHIBITS     1. Total Voting Rights     1 October 2025     Transparency Directive Voting rights and capital   The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. As at 30 September 2025 the issued share capital of AstraZeneca PLC with voting rights is 1,550,701,945 ordinary shares of US$0.25. No shares are held in Treasury. Therefore, the total number of voting rights in AstraZeneca PLC is 1,550,701,945.   The above figure for the total number of voting rights may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, AstraZeneca PLC under the UK Financial Conduct Authority's Disclosure and Transparency Rules.   AstraZeneca   AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit  astrazeneca.com  and follow the Company on social media  @AstraZeneca       Contacts For details on how to contact the Investor Relations Team, please click  here